Bladder Cancer
Bladder cancer is the 6th most common cancer in the United States, affecting patients at a median age of 73-years-old with 11 years of lost life. Ultimately, bladder cancer leads to about 17,000 deaths per year in the United States.
Next generation sequencing has revolutionized our understanding of bladder cancer, and provides us with an excellent opportunity to develop personalized therapies for patients.
Thus - we study ARID1A. ARID1A is a chromatin remodeling tumor suppressor that is mutated (loss of protein) in about 30% of bladder cancers (and in other cancers such as endometrial and gastric cancer). We have taken a synthetic lethal approach to discover new pathways that can be targeted to selectively treat cancer cells with loss of ARID1A. This project utilizes engineered cell lines, molecular pharmacology, cell biology, and mouse models to improve patient lives. See a recent news article below!
Next generation sequencing has revolutionized our understanding of bladder cancer, and provides us with an excellent opportunity to develop personalized therapies for patients.
Thus - we study ARID1A. ARID1A is a chromatin remodeling tumor suppressor that is mutated (loss of protein) in about 30% of bladder cancers (and in other cancers such as endometrial and gastric cancer). We have taken a synthetic lethal approach to discover new pathways that can be targeted to selectively treat cancer cells with loss of ARID1A. This project utilizes engineered cell lines, molecular pharmacology, cell biology, and mouse models to improve patient lives. See a recent news article below!